The Evolving Landscape of Medicaid and CHIP: Implications for Children’s Oral Health

Medicaid and CHIP facilitate necessary access to oral health services, which helps to bridge the gap in dental care for children from low- and moderate-income families. By providing coverage, it ensures that socioeconomic status does not hinder a child’s ability to receive necessary dental services. The post The Evolving Landscape of Medicaid and CHIP: Implications…

Read More

Axsome Aims for FDA Filing in Alzheimer’s Agitation Despite Mixed Bag of Phase 3 Data

One Phase 3 test of Auvelity met its main goal in Alzheimer’s agitation while the drug’s other pivotal trial showed numerical improvement that fell short of statistical significance. Axsome Therapeutics aims to offer an alternative to Rexulti, a Lundbeck and Otsuka Pharmaceutical product that is the only FDA-approved Alzheimer’s agitation drug. The post Axsome Aims…

Read More